Protara Therapeutics
TARA
105 hedge funds and large institutions have $212M invested in Protara Therapeutics in 2025 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 46 increasing their positions, 15 reducing their positions, and 7 closing their positions.
748% more call options, than puts
Call options by funds: $907K | Put options by funds: $107K
357% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 7
207% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 15
86% more capital invested
Capital invested by funds: $114M → $212M (+$98.3M)
30% more funds holding
Funds holding: 81 → 105 (+24)
9.19% more ownership
Funds ownership: 67.95% → 77.14% (+9.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$9.54M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$6.12M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.8M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$5.06M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$4.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Stempoint Capital
New York
|
-$1.58M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.1M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$437K |
| 4 |
CCM
Catalio Capital Management
New York
|
-$303K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$273K |
TARA Hedge Fund Activity: Q4 2025 in Review
105 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2025, worth a combined $212M — up 86% from $114M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new TARA positions and 7 closed out — a net gain of 25 holders — while 46 added to existing stakes and 15 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $9.54M. The largest seller was Stempoint Capital, exiting entirely with an estimated $1.58M sold.
- 105 institutional investors held Protara Therapeutics (TARA) as of Q4 2025, up from 81 in Q3 2025.
- Funds reported $212M of Protara Therapeutics stock for Q4 2025, up 86% quarter-over-quarter.
- 32 funds opened new Protara Therapeutics positions in Q4 2025 and 7 closed out, a net change of +25 holders.
- The largest Protara Therapeutics buyer in Q4 2025 was Sio Capital Management, an estimated $9.54M added.
- The largest Protara Therapeutics seller in Q4 2025 was Stempoint Capital, an estimated $1.58M sold.
Based on aggregated 13F filings for Q4 2025.